Latest Gi Dynamics Inc (GIDYL) Headlines
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
GI Dynamics to Present at Cowen & Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a company developing innovative treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, president and chief executive officer, is scheduled to present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:50 p.m. ET at the Marriott Copley Place in Boston.
GI Dynamics Announces Expanded Reimbursement Coverage in Germany
Business Wire - Mon Feb 03, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that InEk, the German Institute for the Hospital Remuneration System, has assigned NUB (Neue Untersuchungs- und Behandlungsmethoden) Status 1 for EndoBarrier(R) Therapy.
GI Dynamics Announces EndoBarrier(R) Therapy Data to be Presented at Obesity Week
Business Wire - Tue Nov 12, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier(R) Therapy will be presented during three sessions at Obesity Week, taking place in Atlanta, Ga., November 11-16, 2013. This event is a combined annual meeting of The Obesity Society (TOS) and The American Society for Metabolic and Bariatric Surgery (ASMBS).
GI Dynamics to Present at Canaccord Genuity 33rd Annual Growth Conference
Business Wire - Thu Aug 08, 7:00AM CDT
GI Dynamics, Inc. (ASX: GID), announced today that management will present at the Canaccord Genuity 33rd Annual Growth Conference to be held August 14-15, 2013, at the InterContinental Hotel in Boston. Stuart A. Randle, president and chief executive officer, is scheduled to present an overview of the Company on Thursday, Aug. 15 at 3 p.m. ET.
Mintz Levin Represents GI Dynamics, Inc. in $52 Million Private Placements
Business Wire - Wed Jul 17, 10:09AM CDT
Attorneys in the Corporate & Securities Section of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised GI Dynamics, Inc. on two private placements in which the company received commitments from investors in Australia, the United States of America and certain other jurisdictions to raise approximately $52 million.
GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement and Launch of Share Purchase Plan
Business Wire - Tue Jul 02, 6:40PM CDT
GI Dynamics, Inc. (ASX: GID) ("GI Dynamics" or the "Company") is pleased to announce that it has received commitments for an oversubscribed private placement of 108.5 million fully paid CHESS Depositary Interests (CDIs) at an issue price of A$0.53 per CDI to sophisticated, professional and accredited investors in Australia, the United States of America and certain other jurisdictions to raise A$57.5 million (Placement). GI Dynamics intends to use the proceeds raised from the Placement and Share Purchase Plan (see below) to fund its U.S. pivotal clinical trial and for general working capital purposes.
MediFocus: Medical Devices for the Treatment of Obesity
M2 - Fri May 31, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z82f67/medifocus) has announced the addition of the "MediFocus: Medical Devices for the Treatment of Obesity" report to their offering. Medical Devices Strive to Fill Void in Obesity Treatment The obesity medical device industry is expected to experience significant change in the near future, as new products come to market, older products see a decline in sales, physician adoption increases worldwide, and supporting device reimbursement is put in place. While bariatric surgery techniques have demonstrated notable improvements in safety and efficacy compared with years prior, aversion to intervention has curbed operation prevalence to less than 1% of suitable obese candidates. Moreover, diabetes indications further drive obesity medical devices sales by lowering the threshold body mass index for patients to receive implantation, and comorbidities like this can often necessitate intervention. With limited options in regards to pharmacotherapy,
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer
Business Wire - Tue Apr 30, 5:00PM CDT
GI Dynamics, Inc. (ASX: GID) today announced the appointment of David Maggs, M.D. to the position of chief medical officer. In this role, Dr. Maggs will oversee clinical development and medical affairs for the Company's lead product, EndoBarrier(R), a breakthrough therapy for the treatment of type 2 diabetes and/or obesity.
Dr. Atul Madan Reviews Reports on EndoBarrier(R) As A New Weight Loss Method and Compares to Lap Band Surgery
PRWeb - Mon Apr 22, 10:01PM CDT
A new weight loss method, EndoBarrier(R), is making the news in the United States, though clearance hasn't yet been given to market it. EndoBarrier has been allowed within the United States for use in investigations, and a current 500-person trial by GI Dynamics may open up access to the American market by 2017. Bariatric surgeon Dr. Madan analyzes current reports on the new method, and continues to recommend lap band surgery as a proven weight loss method.
GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier(R) Therapy in Brazil
Business Wire - Wed Mar 06, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) today announced that it has entered into an agreement with CMS Medical (CMS), headquartered in Goiania, Brazil, to distribute its lead product, EndoBarrier(R), a breakthrough therapy for type 2 diabetes and/or obesity. Under the agreement, CMS will be the exclusive distributor of EndoBarrier Therapy in Brazil, following regulatory approval of the product in that country.
GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier(R)
Business Wire - Tue Jan 15, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) today announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier(R), the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
GI Dynamics Announces Resolution of Litigation with Gore
Business Wire - Wed Jan 09, 5:32PM CST
GI Dynamics, Inc. (GI Dynamics or the Company) (ASX: GID) today announced that it has reached a settlement with W.L. Gore & Associates (Gore) in litigation brought by Gore in the United States District Court for the District of Arizona ("Court"). Under the settlement, GI Dynamics retains exclusive ownership and control of its patent portfolio, and both parties have dismissed all claims against each other. GI Dynamics has also granted Gore a non-exclusive, royalty-free license to use GI Dynamics' patents, but only in the vasculature (i.e., blood vessels). Gore is not licensed to use GI Dynamics' patents for any applications in the gastrointestinal tract, which is the area of the body in which GI Dynamics' products are designed to be used. Neither side will make any cash payments to the other, nor will any royalties be due.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
GI Dynamics to Present at Cowen & Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a company developing innovative treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, president and chief executive officer, is scheduled to present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:50 p.m. ET at the Marriott Copley Place in Boston.
GI Dynamics Announces Expanded Reimbursement Coverage in Germany
Business Wire - Mon Feb 03, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that InEk, the German Institute for the Hospital Remuneration System, has assigned NUB (Neue Untersuchungs- und Behandlungsmethoden) Status 1 for EndoBarrier(R) Therapy.
GI Dynamics Announces EndoBarrier(R) Therapy Data to be Presented at Obesity Week
Business Wire - Tue Nov 12, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier(R) Therapy will be presented during three sessions at Obesity Week, taking place in Atlanta, Ga., November 11-16, 2013. This event is a combined annual meeting of The Obesity Society (TOS) and The American Society for Metabolic and Bariatric Surgery (ASMBS).
GI Dynamics to Present at Canaccord Genuity 33rd Annual Growth Conference
Business Wire - Thu Aug 08, 7:00AM CDT
GI Dynamics, Inc. (ASX: GID), announced today that management will present at the Canaccord Genuity 33rd Annual Growth Conference to be held August 14-15, 2013, at the InterContinental Hotel in Boston. Stuart A. Randle, president and chief executive officer, is scheduled to present an overview of the Company on Thursday, Aug. 15 at 3 p.m. ET.
Mintz Levin Represents GI Dynamics, Inc. in $52 Million Private Placements
Business Wire - Wed Jul 17, 10:09AM CDT
Attorneys in the Corporate & Securities Section of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised GI Dynamics, Inc. on two private placements in which the company received commitments from investors in Australia, the United States of America and certain other jurisdictions to raise approximately $52 million.
GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement and Launch of Share Purchase Plan
Business Wire - Tue Jul 02, 6:40PM CDT
GI Dynamics, Inc. (ASX: GID) ("GI Dynamics" or the "Company") is pleased to announce that it has received commitments for an oversubscribed private placement of 108.5 million fully paid CHESS Depositary Interests (CDIs) at an issue price of A$0.53 per CDI to sophisticated, professional and accredited investors in Australia, the United States of America and certain other jurisdictions to raise A$57.5 million (Placement). GI Dynamics intends to use the proceeds raised from the Placement and Share Purchase Plan (see below) to fund its U.S. pivotal clinical trial and for general working capital purposes.
MediFocus: Medical Devices for the Treatment of Obesity
M2 - Fri May 31, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z82f67/medifocus) has announced the addition of the "MediFocus: Medical Devices for the Treatment of Obesity" report to their offering. Medical Devices Strive to Fill Void in Obesity Treatment The obesity medical device industry is expected to experience significant change in the near future, as new products come to market, older products see a decline in sales, physician adoption increases worldwide, and supporting device reimbursement is put in place. While bariatric surgery techniques have demonstrated notable improvements in safety and efficacy compared with years prior, aversion to intervention has curbed operation prevalence to less than 1% of suitable obese candidates. Moreover, diabetes indications further drive obesity medical devices sales by lowering the threshold body mass index for patients to receive implantation, and comorbidities like this can often necessitate intervention. With limited options in regards to pharmacotherapy,
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer
Business Wire - Tue Apr 30, 5:00PM CDT
GI Dynamics, Inc. (ASX: GID) today announced the appointment of David Maggs, M.D. to the position of chief medical officer. In this role, Dr. Maggs will oversee clinical development and medical affairs for the Company's lead product, EndoBarrier(R), a breakthrough therapy for the treatment of type 2 diabetes and/or obesity.
Dr. Atul Madan Reviews Reports on EndoBarrier(R) As A New Weight Loss Method and Compares to Lap Band Surgery
PRWeb - Mon Apr 22, 10:01PM CDT
A new weight loss method, EndoBarrier(R), is making the news in the United States, though clearance hasn't yet been given to market it. EndoBarrier has been allowed within the United States for use in investigations, and a current 500-person trial by GI Dynamics may open up access to the American market by 2017. Bariatric surgeon Dr. Madan analyzes current reports on the new method, and continues to recommend lap band surgery as a proven weight loss method.
GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier(R) Therapy in Brazil
Business Wire - Wed Mar 06, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) today announced that it has entered into an agreement with CMS Medical (CMS), headquartered in Goiania, Brazil, to distribute its lead product, EndoBarrier(R), a breakthrough therapy for type 2 diabetes and/or obesity. Under the agreement, CMS will be the exclusive distributor of EndoBarrier Therapy in Brazil, following regulatory approval of the product in that country.
GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier(R)
Business Wire - Tue Jan 15, 5:30AM CST
GI Dynamics, Inc. (ASX: GID) today announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier(R), the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
GI Dynamics Announces Resolution of Litigation with Gore
Business Wire - Wed Jan 09, 5:32PM CST
GI Dynamics, Inc. (GI Dynamics or the Company) (ASX: GID) today announced that it has reached a settlement with W.L. Gore & Associates (Gore) in litigation brought by Gore in the United States District Court for the District of Arizona ("Court"). Under the settlement, GI Dynamics retains exclusive ownership and control of its patent portfolio, and both parties have dismissed all claims against each other. GI Dynamics has also granted Gore a non-exclusive, royalty-free license to use GI Dynamics' patents, but only in the vasculature (i.e., blood vessels). Gore is not licensed to use GI Dynamics' patents for any applications in the gastrointestinal tract, which is the area of the body in which GI Dynamics' products are designed to be used. Neither side will make any cash payments to the other, nor will any royalties be due.
